Research Triangle Park, NC, 2023 –Altis Biosystems will be presenting data using the RepliGut® Model system for intestinal toxicity screening at the Society of Toxicology’s 62nd Annual Meeting and ToxExpo. The RepliGut® Model is a human stem cell derived platform that recreates the intestinal epithelium, enabling physiologically relevant testing of drug candidates in vitro.
Altis will be presenting both a poster and a symposium supporting the utility of the RepliGut® Model at SOT, which is held at the Music City Center in Nashville, TN, March 19-23.
James Levi, Associate Scientist at Altis Biosystems, will be presenting a poster titled “A sensitive and specific human primary stem cell-based in vitro assay for predicting the gastrointestinal toxicity risk of therapeutic agents” on Monday March 20 at 10:45am in the Exhibit Hall. The poster will detail an assay developed to measure GI toxicity potential using the RepliGut® Platform, and present evidence supporting the use of the RepliGut® Platform in preclinical toxicology studies.
Dr. Bill Thelin, Chief Science Officer at Altis Biosystems, will be presenting a symposium “Gastrointestinal toxicity screening using a human stem cell-derived colonic epithelium model” on Wednesday March 22 at 1:30pm in room 101C. His presentation will be focused on describing mechanistic and functional toxicity insights derived from the RepliGut® Model.
The RepliGut® Platform accelerates and improves drug development pipelines
Gastrointestinal (GI) toxicities are the most common drug-induced adverse events in human clinical trials, yet drug developers have limited options for preclinical GI toxicity testing. Current methods use either immortalized GI cell lines or in vivo animal models. Both approaches are time consuming, difficult to implement, and do not reliably anticipate GI response in humans. Without accurate and high throughput in vitro testing models for the human intestine, the risk of drugs moving through to clinical trials with severe intestinal toxicities remains high.
To address these issues, Altis Biosystems has developed the RepliGut® Platform, an in vitro model that recreates the human gastrointestinal epithelium. The RepliGut® Platform is derived from donor stem cells that are differentiated into all key cell types in the human gut epithelium. Compared to cancer or immortalized GI cell line models, the RepliGut® Platform does not rely on a slow culturing process, and more closely replicates in vivo physiology, allowing for high throughput screening and more accurate prediction of inflammation and toxicity.
“We are really looking forward to further connecting with the toxicology community,” said Maureen Bunger, Sr. Director of Marketing and Product Management at Altis Biosystems, of their participation at SOT. “The RepliGut® Platform has the potential to improve understanding of risk for GI toxicity earlier in drug development, thus reducing costs by enabling mitigation prior to clinical trials. We want to identify key partners who can start putting this technology to work.”
To learn more about Altis Biosystems, please stop by booth #1227 or visit altisbiosystems.com.
About Altis Biosystems
Altis Biosystems is a stem-cell technology company that created one of the first human stem-cell derived intestinal cell models for in vitro drug screening and microbiome research—The RepliGut® Model. Altis Biosystems was founded by scientists from the University of North Carolina and is headquartered in Research Triangle Park, NC. The intellectual property behind the RepliGut® Model was created as part of an NIH Transformative Research Award to develop a microfluidic organ-on-a-chip mimic of the human colon. The technology is available as a kit or via Altis Biosystems’ RepliGut® Services. Learn more at altisbiosystems.com.
Media contact
Name: Niki Heinz
Email:
marketing@altisbiosystems.com